MMsyndiTrackTM, our Multiple Myeloma syndicated study includes all recent advances in multiple myeloma treatment with over 12 years track record. Protease inhibitors, immunomodulating agents, and monoclonal antibodies have given patients more options than ever before and enhanced quality of life. Despite these advances, treatment for relapsed/refractory (R/R) multiple myeloma patients continues to be a pressing need. The emergence of chimeric antigen receptor T-cell (CAR-T) therapy promises a new wave of innovation and treatment progress on the horizon.
Capitalizing on our unique expertise in patient chart-based research we have designed, with input from our clients, a syndicated offering based on real world data to monitor the impact of the new treatments on MM management.
Example of recent release (contact us for even more recent data):
- collection up to December 2021
- FR, DE, IT, ES, UK
- 438 Onco-hematologists including 66 from authorized CAR-T centers
- 3,175 real world patient charts
- 623 L1 non SCT
- 346 L1 prior SCT
- 282 L1 post SCT
- 552 L2
- 595 L3
- 538 L4
- 239 L5+
More information about our MM syndicated study?
- Types of data collected
- Dates of research waves
Fill in the form and we will be in touch shortly. 👉